Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study
Roberto Moretto(Azienda Ospedaliera Universitaria Pisana), Chiara Cremolini(University of Pisa), Clara Ugolini(Azienda Ospedaliera Universitaria Pisana), Alfredo Falcone(Azienda Ospedaliero-Universitaria Careggi), Mirella Giordano(University of Pisa), Gabriella Fontanini(University of Pisa), Matteo Clavarezza(Ente Ospedaliero Ospedali Galliera), Sara Lonardi(Istituto Oncologico Veneto), Alessandra Boccaccino(Ospedale "Santa Maria delle Croci" di Ravenna), Gianluca Masi(University of Pisa), Anello Marcello Poma(University of Pisa), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Filippo Pietrantonio(Fondazione IRCCS Istituto Nazionale dei Tumori), Cristina Granetto, Alessandro Passardi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Giuseppe Aprile(Ospedale Santa Maria della Misericordia di Udine), Gianluca Tomasello(Istituti Ospitalieri di Cremona), Veronica Conca(University of Pisa), Alessandro Bertolini(Azienda Socio Sanitaria Territoriale della Valtellina e Alto Lario), Marco Maria Germani(University of Pisa)
Cited by 7
Related Papers
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest
|Journal of Clinical Oncology|2007|1.2k